- Advertise
- Contact Us
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
Heart Failure
The Practical Cardiology(TM) Heart Failure clinical resource center is an information hub for the latest in heart failure and heart failure management. With a focus on heart failure with reduced and preserved ejection fraction (HFrEF and HFpEF) this page features content including articles, videos, podcasts, and clinician-authored columns on FDA approvals, studies, guideline updates, and more.
Menopause Before 50 Could Predict Increased Cardiovascular Disease Risk
August 05, 2022
An analysis of more than 1.4 million women with nearly a decade of follow-up data, a new study suggests entering menopause before the age of 40 was associated with a 33% increase in risk of heart failure, but investigators noted an increasing trend in risk was observed for all women entering menopause before 50 years fo age.
Study Warns of Significant Increases in Diabetes and Cardiovascular Disease by 2060
August 01, 2022
Using data from the 2020 US Census report and recent NHANES survey data, investigators from Massachusetts General Hospital detail expected increases in the prevalence of cardiovascular risk factors and cardiovascular disease among the US population by 2060.
Cardiology Month in Review: July 2022
July 30, 2022
Our cardiology month in review spotlights the most popular content from the past month. The top content from July 2022 includes hormone therapy guidance from NAMS, a look at the potential for increased risk of kidney damage with a popular statin, and a recap of upcoming decisions and trials of interest in cardiometabolic from the second half of 2022.
Women, Minority Patients with Advanced Heart Failure Less Likely to Receive LVAD Devices
July 28, 2022
An analysis of claims data from Medicare Fee-for-Service beneficiaries with advanced heart failure indicates Black patients were nearly 8% less likely to receive an LVAD compared to their White counterparts and female patients were 3% less likely to receive an LVAD than their male counterparts.
NAFLD Linked to Increased Risk of New-Onset Heart Failure
July 26, 2022
A systematic review and meta-analysis of 11 longitudinal cohort studies containing more than 11 million patients suggest presence of NAFLD was associated with a 1.5-fold increase in risk of new-onset heart failure in adjusted models.
Don't Miss a Beat: Understanding GFR Slope, with Brendon Neuen, MBBS, MSc
July 23, 2022
In the latest edition of Don’t Miss a Beat, Drs. Greene and Vaduganathan are joined by special guest Brendon Neuen, MBBS, MSc, of the George Institute of Global Health. A trialist currently contributing to the FIND-CKD trial, Neuen takes Vaduganathan and Greene on a deep dive into the use of GFR slope as an end point in clinical trials and as a tool in clinical practice.
Dapagliflozin's Cardiorenal Benefits Consistent in T2D, Regardless of Background CV Medication Use
July 20, 2022
A secondary analysis of the DECLARE-TIMI 58 trial details the cardiorenal protective benefits of dapagliflozin across subgroups of patients defined by use of background cardiovascular medication use.
Excessive Salt Restriction Could Increase Risk of Negative Outcomes in HFpEF
July 19, 2022
A posthoc analysis of patients in the Americas from the TOPCAT trial provides insight into the relationship between excessive dietary salt restriction and risk of adverse outcomes in patients with heart failure with preserved ejection fraction.
Earlier Follow-Ups Could Reduce Mortality in Heart Failure, Study Finds
July 16, 2022
An analysis of 30- and 90-day readmission rates among patients hospitalized with AMI and CHF in Canada describes the impact of earlier follow-up appointments among these patient populations.
Medicare Advantage Beneficiaries Less Likely to Receive GLP-1 RA and SGLT2 Inhibitor Prescriptions
July 14, 2022
A comparison of data from more than 340,000 Medicare beneficiaries with diabetes provides insight into the real-world differences in the management of these patients, including disparities in the prescription of GLP-1 RAs and SGLT2 inhibitors.